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Abstract
Background: This study examined sex-specific patterns and temporal trends in the incidence of solid tumours
in the Northern Region of England from 1968 to 2005. This updates earlier analyses from the region where sex
was not considered in depth. Sex-specific analyses were carried out to determine whether sex differences might
provide clues to aetiology.
Methods: Details of 3576 cases, aged 0–24 years, were obtained from a specialist population-based cancer
registry. There were 1843 males (886 aged 0–14 years and 957 aged 15–24 years) and 1733 females (791 aged 0–
14 years and 942 aged 15–24 years). Age-standardized incidence rates (per million population) were calculated.
Linear regression was used to analyze temporal trends in incidence and annual percentage changes were
estimated. Analyses were stratified by sex and by age-group.
Results: There were marked differences in incidence patterns and trends between males and females and also
between age-groups. For males central nervous system (CNS) tumours formed the largest proportion of under-
15 cases and germ cell tumours was the largest group in the 15–24's, whilst for females CNS tumours dominated
in the under-15's and carcinomas in the older group. For 0–14 year olds there were male-specific increases in the
incidence of rhabdomyosarcoma (2.4% per annum; 95% CI: 0.2%–4.5%) and non-melanotic skin cancer (9.6%; 95%
CI: 0.0%–19.2%) and female-specific increases for sympathetic nervous system tumours (2.2%; 95% CI: 0.4%–
3.9%), gonadal germ cell tumours (8.6%; 95% CI: 4.3%–12.9%) and non-gonadal germ cell tumours (5.4%; 95% CI:
2.8%–7.9%). For 15–24 year olds, there were male-specific increases in gonadal germ cell tumours (1.9%; 95% CI:
0.3%–3.4%), non-gonadal germ cell tumours (4.4%; 95% CI: 1.1%–7.7%) and non-melanotic skin cancer (4.7%; 95%
CI: 0.5%–8.9%) and female-specific increases for osteosarcoma (3.5%; 95% CI: 0.5%–6.5%), thyroid cancer (2.8%;
95% CI: 0.1%–5.6%) and melanoma (4.6%; 95% CI: 2.2%–7.1%).
Conclusion: This study has highlighted notable differences between the sexes in incidence patterns and trends
for solid tumours. Some of these sex-specific differences could have been obscured if males and females had been
analysed together. Furthermore, they suggest aetiological differences or differential susceptibility to
environmental factors between males and females.
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Sex-related differences in incidence of childhood cancer
are well-established and consistent worldwide [1-4]. Sex
of the patient can also play a role in efficiency of diagnosis
and treatment [5]. Therefore it is important to include
both male and female results in reported trends, even for
childhood and young persons' cancers.
Unfortunately this has not always been done. For
instance, a recent paper reported solid tumour rates in
north-west Italy over a similar time period of 1967–2001
[6]. Sex ratios have been given where the incidence rates
were reported. However, in calculating the annual average
percentage rate change the sexes have been combined.
Other papers have also reported overall and not sex-spe-
cific results [7]. This may have obscured sex-specific tem-
poral trends, especially over an extended time period.
Previous studies from the Northern Region of England
have assessed the incidence of solid tumours diagnosed in
0 – 24 year olds during the periods 1968 – 1982 and 1968
– 1995 [8,9]. Another study from the Northern region has
focused specifically on the 15–24 age group [10]. These
studies have found that the overall incidence of solid
tumours is rising in the area. This is a trend which is in
agreement with a number of other studies from other
parts of Europe and elsewhere in the world [7,11-14].
The present study updates the previous analyses from the
Northern Region of England and, more specifically exam-
ines sex-specific trends in the incidence of individual diag-
nostic groups. It was hypothesized that diagnostic groups
that show only marginal or non-statistically significant
results when the sexes are pooled would show more dis-
tinct and significant results when examined by sex.
The aim of this study was to determine whether there were
sex-specific trends in the incidence of solid tumours in the
Northern Region of England. It is well known that cancer
patterns are substantially different between children and
the group comprising adolescents and young adults. Thus,
analyses were stratified by age-group (0 – 14 year olds and
15 – 24 year olds).
Methods
Study Subjects
All cases of solid tumours in 0 – 24 year olds diagnosed in
the Northern Region of England during the period 1968 –
2005 were obtained from the Northern Region Young Per-
sons' Malignant Disease Registry (NRYPMDR). The NRYP-
MDR is a specialist cancer registry covering the counties of
Northumberland, Tyne and Wear, Durham, Teesside and
Cumbria (excluding Barrow-in-Furness). All cases of
malignant disease in the region occurring in residents
aged under-25 are reported to the registry. The entire
region contains about 17% of the under-25 population of
England. Tyne and Wear is the 6th largest conurbation in
the country and the largest population centre in the study
area. The population of the Northern Region is ethnically
homogeneous, with fewer than 2% from ethnic minori-
ties [15-17]. Less than 3% born of its population was born
outside of the UK, the lowest of any region in England and
Scotland, and is similar to Wales [18].
Cases aged 0–14 years have been collected prospectively
since 1968. Cases aged 15–24 years have been collected
retrospectively for cases diagnosed during 1968–1985 and
prospectively since 1985. Cases are identified from multi-
ple sources. Consultants throughout the region notify the
registry of any malignancies in children and young adults.
Death certificates and hospital admissions are regularly
examined. Data are thoroughly cross-checked with
regional and national cancer registries at regular intervals.
This ensures that information is highly accurate and com-
plete. The same rigorous procedures were applied to the
retrospective collection of data on 15–24 year olds for the
period 1968–1985. Overall, it has been estimated that
ascertainment of cases in 0–24 year olds is greater than
98% [9,19]. The International Classification of Diseases
for Oncology (ICDO-2) was used for coding of morphol-
ogy and primary site of diagnosis [20]. Cases were
grouped using a modification of the International Classi-
fication of Childhood Cancer (ICCC) [21].
Statistical Methods
Incidence rates per million population were calculated
based on mid-year population estimates for the study
region obtained from the Office for National Statistics.
Age-standardized rates (ASRs) and 95% confidence inter-
vals (CIs) were calculated based on a standard world pop-
ulation [22]. ASRs (and 95% CIs) were calculated
separately for males and females in childhood (aged 0–
14) and adolescence/young adulthood (aged 15–24).
This was done for the entire study period (1968–2005)
and also for three shorter time periods (1968–1980,
1981–1993, 1994–2005) to assess temporal variation.
Temporal trends in annual ASRs were analysed using a lin-
ear regression model that included year as a covariate. Fur-
thermore, a significance test for a male/female difference
in trend was obtained by including covariates year, sex
and the interaction term year* sex in a linear regression
model. Statistical significance was taken as P < 0.05.
Results
There were a total of 3576 cases of primary solid tumour
diagnosed during the period 1968–2005. 1843 were in
males, of whom 886 were aged 0–14 and 957 were aged
15–24. 1733 were in females, of whom 791 were aged 0–
14 and 942 were aged 15–24. Overall numbers of cases
and age-standardized rates (per million population) withPage 2 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:89 http://www.biomedcentral.com/1471-2407/8/89
Page 3 of 9
(page number not for citation purposes)
Table 1: Numbers of cases and age-standardized rates (per million population) with 95% confidence intervals (CIs) by diagnosis, age-
group and sex, 1968–2005
Ages 0–14 Ages 15–24
No. Rate (95% CI) No. Rate (95% CI)
CNS tumours M 382 31.7 (28.5,35.0) 224 27.3 (23.7,30.9)
F 309 27.6 (24.4,30.7) 165 20.2 (17.1,23.3)
Ependymomas M 51 4.6 (3.3,5.8) 21 2.6 (1.6,3.9)
F 21 2.0 (1.2,3.1) 6 0.8 (0.3,1.6)
Astrocytomas M 137 11.1 (9.2,12.9) 76 9.3 (7.2,11.4)
F 126 11.2 (9.2,13.1) 54 6.6 (4.8,8.4)
PNET M 78 6.7 (5.2,8.2) 13 1.6 (0.8,2.7)
F 45 4.2 (3.0,5.4) 7 0.9 (0.4,1.8)
Other gliomas M 34 2.9 (1.9,3.8) 36 4.3 (2.9,5.8)
F 34 3.0 (2.0,4.0) 26 3.2 (2.1,4.7)
Sympathetic nervous system tumours M 102 9.8 (7.9,11.7) 9 1.1 (0.5,2.1)
F 95 9.7 (7.8,11.7) 9 1.1 (0.5,2.2)
Retinoblastoma M 38 3.9 (2.6,5.1) 0 -
F 50 5.4 (3.9,6.8) 0 -
Renal tumours M 71 6.8 (5.2,8.4) 8 0.9 (0.4,1.8)
F 85 8.7 (6.9,10.6) 7 0.8 (0.3,1.7)
Hepatoblastomas M 7 0.7 (0.3,1.5) 0 -
F 10 1.0 (0.5,1.9) 2 0.2 (0.0,0.8)
Bone tumours M 65 4.7 (3.5,5.8) 114 14.2 (11.6,16.8)
F 56 4.3 (3.2,5.5) 66 8.3 (6.3,10.3)
Osteosarcoma M 34 2.4 (1.6,3.3) 60 7.5 (5.6,9.5)
F 37 2.8 (1.9,3.8) 39 4.9 (3.4,6.5)
Ewing's sarcoma M 29 2.1 (1.4,3.0) 36 4.5 (3.0,5.9)
F 16 1.3 (0.7,2.1) 16 2.0 (1.2,3.3)
Soft tissue sarcomas M 127 11.0 (9.1,13.0) 89 10.9 (8.6,13.2)
F 72 6.2 (4.8,7.7) 94 11.7 (9.3,14.0)
Rhabdomyosarcoma M 75 6.8 (5.3,8.4) 14 1.8 (1.0,3.0)
F 39 3.6 (2.5,4.7) 21 2.7 (1.6,4.1)
Other M 52 4.2 (3.0,5.4) 75 9.1 (7.1,11.2)
F 33 2.6 (1.7,3.5) 73 9.0 (6.9,11.1)
Germ cell tumours M 55 5.2 (3.8,6.6) 292 34.8 (30.8,38.8)
F 60 5.5 (4.1,6.9) 127 15.4 (12.7,18.1)
Gonadal M 32 3.2 (2.1,4.3) 260 31.0 (27.2,34.7)
F 18 1.4 (0.8,2.2) 86 10.4 (8.2,12.6)
Non-gonadal M 23 2.0 (1.3,3.0) 32 3.8 (2.5,5.2)
F 42 4.1 (2.9,5.4) 41 5.0 (3.5,6.6)
Carcinomas M 39 2.9 (2.0,3.9) 221 26.4 (22.9,29.9)
F 54 4.5 (3.3,5.7) 472 56.5 (51.4,61.6)
Thyroid M 9 0.7 (0.3,1.3) 23 2.8 (1.7,4.1)
F 9 0.7 (0.3,1.4) 61 7.4 (5.6,9.3)
Melanoma M 7 0.5 (0.2,1.1) 61 7.4 (5.5,9.2)
F 16 1.4 (0.8,2.3) 148 17.9 (15.0,20.7)
Skin M 4 0.3 (0.1,0.7) 39 4.6 (3.1,6.0)
F 4 0.3 (0.1,0.7) 43 5.2 (3.6,6.7)
Breast M 0 - 1 0.1 (0.0,0.7)
F 0 - 42 4.9 (3.4,6.4)
Genital/other reproductive M 0 - 0 -
F 1 0.1 (0.0,0.6) 85 9.9 (7.8,12.0)
Lung and bronchial M 1 0.1 (0.0,0.4) 7 0.8 (0.3,1.7)
F 2 0.1 (0.0,0.5) 5 0.6 (0.2,1.4)
Colorectal M 0 - 19 2.3 (1.4,3.6)
F 2 0.1 (0.0,0.5) 9 1.1 (0.5,2.0)
TOTAL M 886 76.8 (71.7,81.9) 957 115.7 (108.3,123.0)
F 791 73.0 (67.8,78.1) 942 114.3 (107.0,121.6)
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and sex, are given for the entire time period (1968–2005)
in Table 1. Solid tumours in males aged 0–14 years were
dominated by central nervous system (CNS) tumours
(43.1%), with soft tissue sarcomas (14.3%) and sympa-
thetic nervous system tumours (11.5%) being the next
most predominant groups, whilst for males aged 15–24
germ cell tumours (30.5%), CNS tumours (23.4%) and
carcinomas (23.1%) were the largest diagnostic groups.
27.6% of the male carcinomas in the 15–24 year old
group were melanomas. For females aged 0–14 years CNS
tumours (39.1%), sympathetic nervous system tumours
(12.0%) and renal tumours (10.7%) were the three most
common types of solid tumour. However, females aged
15–24 years presented a contrasting spectrum to males
from this age-group. Carcinomas (50.1%) dominated the
diagnoses, followed by CNS tumours (17.5%) and germ
cell tumours (13.5%) in these ages. Carcinomas in
females aged 15–24 years included large proportions of
melanomas (31.4%) and thyroid cancer (12.9%). A large
proportion of the carcinomas (18.0%) were also tumours
in the genital and other reproductive areas, and 8.9% of
carcinomas were breast tumours.
The results of the analyses of trends are shown in Tables 2
and 3. For 0–14 year olds, there were overall statistically
significant increases for both sexes. There was also an
increase in incidence for both male and female CNS
tumours in 0–14 year olds (males: 1.5% per year; 95% CI:
0.5–2.5 and females: 1.2% per year; 95% CI: 0.2%–
2.2%). This was due to increases in the incidence of astro-
cytoma (males: 3.1% per year; 95% CI: 1.7%–4.6% and
females: 4.4% per year; 95% CI: 2.3%–6.6%). There were
a number of sex-specific incidence trends for 0–14 year
olds. Male-specific increases were observed for rhabdomy-
osarcoma (average annual increase of 2.4%, 95% CI:
0.2%–4.5%), carcinomas overall (3.2% per year, 95% CI:
0.1%–6.3%) and non-melanotic skin cancer (9.6% per
year, 95% CI: 0.0%–19.2%). There were female-specific
increases for sympathetic nervous system tumours (2.2%
per year; 95% CI: 0.4%–3.9%), gonadal germ cell
tumours (8.6% per year; 95% CI: 4.3%–12.9%) and non-
gonadal germ cell tumours (5.4% per year; 95% CI: 2.8%–
7.9%).
For 15–24 year olds, there was an overall statistically sig-
nificant increase for females, but not males. There were
male-specific increases in gonadal germ cell tumours
(1.9% per year, 95% CI: 0.3%–3.4%), non-gonadal germ
cell tumours (4.4% per year, 95% CI: 1.1%–7.7%) and
non-melanotic skin cancer (4.7% per year, 95% CI: 0.5%–
8.9%). There were female-specific increases for osteosar-
coma (3.5% per year; 95% CI: 0.5%–6.5%), carcinomas
overall (2.2% per year; 95% CI: 0.7%–3.7%), thyroid can-
cer (2.8% per year; 95% CI: 0.1%–5.6%) and melanoma
(4.6% per year; 95% CI: 2.2%–7.1%).
There were statistically significant differences in temporal
trends between the sexes for gonadal germ cell tumours in
0–14 year olds (P = 0.001) and melanoma in 15–24 year
olds (P = 0.03). There was also a statistically significant
difference for colorectal tumours in 15–24 year olds (P =
0.01).
Discussion
There was an overall significant increase in the incidence
of childhood solid tumours within this region. This find-
ing was consistent with similar data from other countries
[12]. Long-term temporal trends, reported in studies from
North West England (an area geographical adjacent to the
Northern Region), have also found similar results in the
under-15 population [13,14]. However many similar
papers have reported incidence patterns and temporal
trends but have not reported results stratified by sex. Our
analyses showed sex-specific differences both in the inci-
dence and trends of certain diagnostic types. Most notably
in the 15–24 year olds there were major difference in the
distribution of diagnoses between males and females.
Carcinomas exhibited a marked female excess in this age-
group, which was due to the female preponderance of
melanoma, thyroid and breast carcinoma. Furthermore,
the overall rise in incidence in the adolescent and young
adult group was confined to females.
There were male-specific increases in the incidence of
rhabdomyosarcoma (childhood cases), gonadal and non-
gonadal germ cell tumours (adolescent and young adult
cases) and non-melanotic skin cancer (all ages). There
were female-specific increases in the incidence of sympa-
thetic nervous system tumours, gonadal and non-gonadal
germ cell tumours (childhood cases), osteosarcoma, thy-
roid cancer and melanoma (adolescent and young adult
cases). Sex-related differences in exposure or response to
an aetiological agent that is increasing in prevalence may
be predicted to lead to sex-specific differentials in secular
trends.
Whilst the increase in the incidence of rhabdomyosar-
coma was based on small numbers of cases, an increase in
the incidence of rhabdomyosarcoma has also been
reported by other studies [7,23]. The reason for the
increase is not clear. The aetiology of rhabdomyosarcoma
is likely to be different from the other types of soft tissue
sarcoma (which generally present at older ages). A
number of environmental exposures, including pesti-
cides, dioxin, chlorophenol and benzene, have been
linked particularly with increased risk of other types of
soft tissue sarcoma [24-28]. The present finding, althoughPage 4 of 9
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Table 2: Numbers of cases aged 0–14 years, age-standardized rates (per million population) and 95% CIs, average annual percentage 
rate changes and 95% CIs, by diagnosis, sex and time period and test for sex-difference in temporal trend (P-value)
1968–1980 1981–1993 1994–2005 % Ann. Inc M/F diff
CNS tumours Male 134 28.5 (23.6,33.4) 115 29.9 (24.4,35.4) 133 38.4 (31.8,45.0) 1.5 (0.5,2.5) 0.74
Female 116 26.2 (21.3,31.0) 91 25.1 (19.9,30.3) 102 32.7 (26.3,39.2) 1.2 (0.2,2.2)
Ependymomas Male 18 4.3 (2.5,6.8) 17 4.7 (2.7,7.5) 16 4.9 (2.8,8.0) 0.7 (-1.7,3.2) 0.61
Female 10 2.4 (1.2,4.5) 6 1.6 (0.6,3.5) 5 1.9 (0.6,4.5) -0.5 (-4.6,3.6)
Astrocytomas Male 38 7.9 (5.4,10.5) 44 11.1 (7.8,14.4) 55 15.5 (11.3,19.6) 3.1 (1.7,4.6) 0.33
Female 36 8.1 (5.4,10.8) 29 7.9 (5.3,11.4) 61 19.5 (14.5,24.5) 4.4 (2.3,6.6)
PNET Male 35 7.5 (4.9,10.0) 16 4.4 (2.5,7.2) 27 8.1 (5.3,11.8) 0.6 (-1.6,2.9) 0.86
Female 16 3.8 (2.1,6.1) 15 4.3 (2.4,7.1) 14 4.7 (2.5,7.8) 0.9 (-1.7,3.6)
Other gliomas Male 13 2.9 (1.5,5.0) 10 2.6 (1.2,4.7) 11 3.1 (1.5,5.6) 0.7 (-2.4,3.9) 0.42
Female 15 3.4 (1.9,5.6) 9 2.6 (1.2,4.9) 10 2.9 (1.4,5.4) -1.0 (-3.7,1.7)
Sympathetic nervous system 
tumours
Male 32 7.4 (4.8,10.0) 43 12.6 (8.9,16.4) 27 9.6 (6.3,14.0) 0.9 (-0.5,2.4) 0.29
Female 25 6.9 (4.5,10.2) 34 10.3 (6.8,13.8) 36 13.3 (8.9,17.6) 2.2 (0.4,3.9)
Retinoblastoma Male 16 4.2 (2.4,6.8) 12 3.6 (1.9,6.3) 10 3.6 (1.7,6.6) -0.3 (-3.6,3.1) 0.42
Female 26 7.2 (4.7,10.5) 17 5.4 (3.1,8.6) 7 2.7 (1.1,5.6) -2.1 (-5.0,0.8)
Renal tumours Male 28 6.8 (4.5,9.9) 18 5.1 (3.0,8.0) 25 9.0 (5.8,13.3) 0.5 (-1.5,2.6) 0.86
Female 31 8.3 (5.3,11.2) 29 8.8 (5.9,12.7) 25 9.4 (6.1,13.9) 0.3 (-1.5,2.1)
Hepatoblastomas Male 1 0.3 (0.0,1.5) 1 0.3 (0.0,1.7) 5 1.9 (0.6,4.4) 7.3 (-0.2,14.9) 0.18
Female 5 1.3 (0.4,3.0) 2 0.6 (0.1,2.3) 3 1.2 (0.2,3.4) 0.5 (-5.5,6.6)
Bone tumours Male 30 5.3 (3.4,7.2) 17 4.0 (2.3,6.4) 18 4.6 (2.7,7.3) 0.3 (-2.1,2.7) 0.58
Female 21 4.1 (2.5,6.3) 21 5.1 (3.1,7.8) 14 3.8 (2.1,6.4) -0.7 (-3.3,1.9)
Osteosarcoma Male 18 3.1 (1.9,5.0) 8 1.9 (0.8,3.8) 8 2.0 (0.9,3.9) -0.9 (-4.3,2.6) 0.80
Female 16 3.1 (1.8,5.1) 12 2.9 (1.5,5.0) 9 2.5 (1.1,4.7) -1.5 (-4.2,1.3)
Ewing's sarcoma Male 12 2.2 (1.1,3.8) 9 2.0 (0.9,3.9) 8 2.0 (0.9,4.0) 0.3 (-2.4,3.0) 0.94
Female 4 0.8 (0.2,2.2) 9 2.2 (1.0,4.2) 3 0.8 (0.2,2.4) 0.1 (-4.9,5.1)
Soft tissue sarcomas Male 45 9.6 (6.7,12.4) 46 12.5 (8.9,16.2) 36 11.2 (7.5,14.9) 1.3 (-0.2,2.8) 0.70
Female 28 6.0 (4.0,8.7) 22 5.8 (3.6,8.8) 22 7.0 (4.4,10.7) 0.8 (-1.2,2.9)
Rhabdomyosarcoma Male 24 5.4 (3.4,8.1) 26 7.2 (4.7,10.6) 25 8.3 (5.3,12.3) 2.4 (0.2,4.5) 0.09
Female 19 4.3 (2.5,6.7) 10 2.7 (1.3,5.1) 10 3.7 (1.7,6.7) -0.4 (-2.7,1.9)
Other Male 21 4.2 (2.6,6.4) 20 5.3 (3.2,8.2) 11 2.9 (1.4,5.2) -0.4 (-2.9,2.1) 0.19
Female 9 1.7 (0.8,3.3) 12 3.1 (1.6,5.4) 12 3.4 (1.7,5.9) 2.5 (-1.1,6.0)
Germ cell tumours Male 17 4.4 (2.5,7.0) 18 5.1 (3.0,8.1) 20 6.5 (4.0,10.2) 2.1 (-0.7,4.8) 0.02
Female 8 1.8 (0.7,3.5) 20 5.7 (3.5,8.9) 32 10.6 (6.9,14.4) 6.2 (4.1,8.3)
Gonadal Male 13 3.4 (1.8,5.8) 13 3.9 (2.1,6.6) 6 2.1 (0.8,4.6) -1.1 (-4.9,2.7) 0.001
Female 2 0.4 (0.0,1.3) 2 0.5 (0.1,1.8) 14 4.0 (2.1,6.7) 8.6 (4.3,12.9)
Non-gonadal Male 4 1.0 (0.3,2.5) 5 1.2 (0.4,2.9) 14 4.4 (2.4,7.5) 7.2 (2.6,11.8) 0.50
Female 6 1.4 (0.5,3.1) 18 5.2 (3.1,8.3) 18 6.6 (3.9,10.5) 5.4 (2.8,7.9)
Carcinomas Male 11 2.0 (1.0,3.7) 13 3.0 (1.6,5.1) 15 4.2 (2.3,6.9) 3.2 (0.1,6.3) 0.31
Female 17 3.8 (2.2,6.1) 20 5.0 (3.0,7.7) 17 5.0 (2.9,8.0) 1.1 (-1.5,3.7)
Thyroid Male 2 0.4 (0.0,1.3) 2 0.5 (0.1,1.7) 5 1.3 (0.4,3.0) 5.9 (-0.4,12.2) 0.07
Female 4 0.9 (0.2,2.4) 3 0.7 (0.1,2.0) 2 0.6 (0.1,2.0) -1.8 (-7.1,3.4)
Melanoma Male 2 0.3 (0.0,1.2) 3 0.7 (0.1,2.0) 2 0.6 (0.1,2.3) 4.3 (-2.8,11.4) 0.81
Female 3 0.7 (0.1,2.2) 8 2.1 (0.9,4.1) 5 1.6 (0.5,3.7) 3.1 (-2.7,9.0)
Skin Male 0 - 2 0.4 (0.1,1.5) 2 0.5 (0.1,1.9) 9.6 (0.0,19.2) 0.46
Female 0 - 2 0.5 (0.1,1.6) 2 0.5 (0.1,1.8) 4.5 (-4.8,13.8)
Breast Male 0 - 0 - 0 - - -
Female 0 - 0 - 0 - -
Genital/other reproductive Male 0 - 0 - 0 - - -
Female 0 - 1 0.3 (0.0,1.8) 0 - 2.9 (-15.1,20.9)
Lung and bronchial Male 1 0.2 (0.0,1.1) 0 - 0 - -12.1 (-25.9,1.6) 0.12
Female 1 0.2 (0.0,1.0) 0 - 1 0.3 (0.0,1.4) 2.8 (-9.6,15.2)
Colorectal Male 0 - 0 - 0 - - -
Female 1 0.2 (0.0,1.0) 0 - 1 0.3 (0.0,1.4) 2.5 (-9.9,14.8)
TOTAL Male 314 68.6 (60.8,76.3) 283 76.1 (67.1,85.0) 289 89.0 (78.6,99.4) 1.3 (0.7,1.9) 0.84
Female 277 65.4 (57.6,73.2) 256 71.8 (62.9,80.7) 258 85.7 (75.0,96.3) 1.2 (0.5,2.0)
Figures are counts, ASRs with 95% CIs, Annual Percentage Change in ASR with 95% CIs (estimated from linear regression model) and p value for 
testing M/F difference in trend (obtained from year *sex interaction term in linear regression model)
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Table 3: Numbers of cases aged 15–24 years, age-standardized rates (per million population) and 95% CIs, average annual percentage 
rate changes and 95% CIs, by diagnosis, sex and time period and test for sex-difference in temporal trend (P-value)
1968–1980 1981–1993 1994–2005 % Ann Inc M/F diff
CNS tumours Male 87 29.0 (22.9,35.1) 84 28.4 (22.3,34.5) 53 23.6 (17.3,30.0) -0.5 (-1.9,0.8) 0.60
Female 59 19.8 (14.7,24.8) 59 20.2 (15.1,25.4) 47 20.8 (14.9,26.8) 0.0 (-1.5,1.5)
Ependymomas Male 8 2.7 (1.2,5.3) 10 3.4 (1.6,6.3) 3 1.3 (0.3,3.9) -2.1 (-5.5,1.4) 0.19
Female 2 0.7 (0.1,2.5) 1 0.4 (0.0,2.1) 3 1.3 (0.3,3.9) 3.2 (-3.9,10.3)
Astrocytomas Male 28 9.4 (6.2,13.6) 25 8.6 (5.6,12.7) 23 10.2 (6.5,15.3) 0.4 (-1.9,2.7) 0.71
Female 21 7.0 (4.4,10.8) 17 5.8 (3.4,9.3) 16 7.1 (4.0,11.5) -0.2 (-2.4,2.0)
PNET Male 8 2.6 (1.1,5.2) 3 1.0 (0.2,2.9) 2 0.9 (0.1,3.2) -2.8 (-7.9,2.2) 0.99
Female 4 1.4 (0.4,3.5) 2 0.7 (0.1,2.5) 1 0.5 (0.0,2.6) -2.9 (-8.8,3.1)
Other gliomas Male 14 4.6 (2.5,7.8) 17 5.6 (3.3,9.0) 5 2.2 (0.7,5.2) -1.4 (-4.4,1.5) 0.99
Female 11 3.6 (1.8,6.5) 10 3.6 (1.7,6.7) 5 2.2 (0.7,5.1) -1.4 (-5.3,2.4)
Sympathetic nervous 
system tumours
Male 1 0.3 (0.0,1.8) 6 2.1 (0.8,4.6) 2 0.9 (0.1,3.2) 1.5 (-4.1,7.0) 0.71
Female 2 0.7 (0.1,2.4) 3 1.1 (0.2,3.1) 4 1.9 (0.5,4.8) 3.1 (-3.4,9.7)
Retinoblastoma Male 0 - 0 - 0 - - -
Female 0 - 0 - 0 - -
Renal tumours Male 1 0.3 (0.0,1.8) 3 1.0 (0.2,2.9) 4 1.7 (0.5,4.3) 2.8 (-4.0,9.6) 0.32
Female 3 1.0 (0.2,3.0) 3 0.9 (0.2,2.7) 1 0.4 (0.0,2.4) -1.8 (-7.9,4.3)
Hepatoblastomas Male 0 - 0 - 0 - - -
Female 1 0.3 (0.0,1.8) 1 0.3 (0.0,1.7) 0 - -4.4 (-16.0,7.3)
Bone tumours Male 36 12.1 (8.2,16.1) 50 17.7 (12.8,22.6) 28 12.6 (8.4,18.3) 0.2 (-1.7,2.0) 0.15
Female 19 6.4 (3.9,10.0) 22 7.9 (4.9,11.9) 25 11.6 (7.5,17.1) 2.2 (0.2,4.2)
Osteosarcoma Male 20 6.8 (4.2,10.6) 23 8.2 (5.2,12.3) 17 7.7 (4.5,12.3) 0.1 (-2.6,2.8) 0.10
Female 10 3.4 (1.6,6.2) 12 4.3 (2.2,7.5) 17 7.9 (4.6,12.7) 3.5 (0.5,6.5)
Ewing's sarcoma Male 9 3.0 (1.4,5.7) 20 7.0 (4.3,10.8) 7 3.2 (1.3,6.6) 1.0 (-1.9,4.0) 0.50
Female 6 2.1 (0.8,4.5) 5 1.7 (0.6,4.1) 5 2.3 (0.8,5.4) -0.7 (-4.8,3.4)
Soft tissue sarcomas Male 27 9.1 (6.0,13.3) 29 9.9 (6.6,14.2) 33 14.6 (9.6,19.6) 1.9 (-0.4,4.2) 0.55
Female 27 9.2 (6.1,13.4) 39 13.3 (9.1,17.5) 28 12.7 (8.4,18.4) 1.0 (-0.8,2.9)
Rhabdomyosarcoma Male 5 1.7 (0.6,4.0) 2 0.7 (0.1,2.6) 7 3.2 (1.3,6.6) 3.0 (-1.5,7.5) 0.74
Female 4 1.4 (0.4,3.6) 13 4.6 (2.5,7.9) 4 1.8 (0.5,4.5) 2.0 (-2.2,6.1)
Other Male 22 7.4 (4.6,11.2) 27 9.1 (6.0,13.3) 26 11.4 (7.5,16.7) 1.7 (-1.0,4.4) 0.60
Female 23 7.8 (4.9,11.7) 26 8.7 (5.7,12.7) 24 10.9 (7.0,16.3) 0.7 (-1.7,3.2)
Germ cell tumours Male 70 23.1 (17.7,28.6) 115 37.5 (30.6,44.4) 107 46.5 (37.7,55.3) 2.1 (0.6,3.7) 0.74
Female 44 14.6 (10.3,18.9) 35 11.6 (7.8,15.5) 48 21.6 (15.5,27.7) 1.7 (-0.2,3.6)
Gonadal Male 65 21.5 (16.2,26.7) 101 32.8 (26.4,39.3) 94 40.9 (32.6,49.1) 1.9 (0.3,3.4) 0.51
Female 29 9.6 (6.4,13.8) 26 8.6 (5.6,12.7) 31 13.8 (9.0,18.7) 1.0 (-1.0,3.0)
Non-gonadal Male 5 1.7 (0.5,3.9) 14 4.6 (2.5,7.8) 13 5.6 (3.0,9.6) 4.4 (1.1,7.7) 0.65
Female 15 5.0 (2.8,8.2) 9 3.0 (1.4,5.7) 17 7.8 (4.5,12.4) 3.2 (-0.7,7.1)
Carcinomas Male 78 25.7 (20.0,31.4) 75 24.6 (19.0,30.2) 68 29.7 (22.6,36.8) 0.2 (-1.4,1.8) 0.07
Female 131 43.1 (35.7,50.5) 164 53.9 (45.6,62.1) 177 78.2 (66.7,89.7) 2.2 (0.7,3.7)
Thyroid Male 6 2.0 (0.7,4.3) 8 2.8 (1.2,5.5) 9 3.9 (1.8,7.4) 2.5 (-2.2,7.2) 0.90
Female 13 4.4 (2.3,7.5) 22 7.4 (4.6,11.3) 26 11.5 (7.5,16.9) 2.8 (0.1,5.6)
Melanoma Male 20 6.7 (4.1,10.4) 22 7.2 (4.5,10.9) 19 8.3 (5.0,13.0) 0.6 (-2.1,3.3) 0.03
Female 25 8.3 (5.3,12.2) 54 17.8 (13.0,22.5) 69 30.8 (23.5,38.1) 4.6 (2.2,7.1)
Skin Male 9 2.9 (1.3,5.5) 9 2.9 (1.3,5.5) 21 9.1 (5.6,13.8) 4.7 (0.5,8.9) 0.61
Female 11 3.6 (1.8,6.5) 12 4.1 (2.1,7.1) 20 8.8 (5.4,13.6) 3.2 (-0.4,6.9)
Breast Male 0 - 0 - 1 0.5 (0.0,2.6) 11.8 (-8.4,32.0) 0.25
Female 14 4.5 (2.5,7.6) 18 5.7 (3.4,9.0) 10 4.3 (2.1,8.0) -0.3 (-2.9,2.3)
Genital/other reproductive Male 0 - 0 - 0 - - -
Female 31 10.0 (6.5,13.5) 28 8.8 (5.9,12.8) 26 11.3 (7.4,16.6) 0.5 (-1.7,2.8)
Lung and bronchial Male 4 1.3 (0.4,3.4) 3 1.0 (0.2,2.9) 0 - -6.2 (-12.5,0.2) 0.23
Female 2 0.7 (0.1,2.4) 1 0.3 (0.0,1.7) 2 0.9 (0.1,3.3) 0.0 (-7.7,7.8)
Colorectal Male 10 3.3 (1.6,6.1) 5 1.7 (0.6,4.0) 4 1.7 (0.5,4.4) -3.5 (-7.4,0.4) 0.01
Female 1 0.3 (0.0,1.8) 3 1.0 (0.2,2.9) 5 2.2 (0.7,5.0) 8.2 (0.1,16.3)
TOTAL Male 300 99.8 (88.5,111.1) 362 121.1 (108.6,133.6) 295 129.7 (114.9,144.5) 0.8 (-0.2,1.8) 0.30
Female 286 95.2 (84.1,106.2) 326 109.2 (97.3,121.1) 330 147.2 (131.3,163.1) 1.6 (0.5,2.7)
Figures are counts, ASRs with 95% CIs, Annual Percentage Change in ASR with 95% CIs (estimated from linear regression model) and p value for 
testing M/F difference in trend (obtained from year *sex interaction term in linear regression model)
BMC Cancer 2008, 8:89 http://www.biomedcentral.com/1471-2407/8/89based on small numbers, indicates the possibility of sex-
linked differences in aetiology for rhabdomyosarcoma.
Rises in the incidence of sympathetic nervous system
tumours (mainly neuroblastoma) have been found in
both males and females in other studies [7]. However, the
female-specific increase is consistent with a similar find-
ing that was reported from the Manchester Children's
Tumour Registry [14]. Increased risk of neuroblastoma
has been associated with prenatal and perinatal risk fac-
tors. These have included gestational diabetes and mater-
nal use of medication and hair dyes during pregnancy [29-
31]. The finding from the present study indicates that
there may be differential susceptibility to early exposures
between males and females.
Thyroid cancer exhibits a marked female excess and this is
true in cases among young people [32]. In England and
Wales the ratio of female to male cases is 2.5:1 for those
aged 0–14 [12]. The reasons for this excess are not clear,
but may be due to greater female susceptibility to a trigger-
ing environmental exposure. Our results show a sustained
excess and increase in incidence for females, which merits
closer examination in the future in order to better under-
stand aetiology.
For malignant melanoma the earlier reported temporal
increase [10] has been shown here to be sustained and
concentrated within females aged over 14 years.
Melanoma has been associated with exposure to UV radi-
ation [33]. Our results show a far higher incidence of
melanomas in young adult females than similar males
and a strikingly high annual rate of increase in incidence
of around 5% in females aged 15–24 years. Considering
number of nevi as the best predictor of melanoma occur-
rence [34], previous studies of European schoolchildren
have shown males to have a higher count of small nevi
than females [35]. However, our results show a female
excess in melanoma. This highlights a sex-specific phe-
nomenon, and suggests females in the region may be
exposed to increased UV radiation, perhaps through tan-
ning beds, sunbathing, foreign holidays and mode of
clothing.
The findings for gonadal germ cell tumours in males,
dominating testicular cancer, are consistent with other
studies showing that the incidence has risen dramatically
elsewhere in the developed world [36,37]. A previous
report from this region highlighted this increase and
noted that 80% of the tumours are non-seminomas,
which tend to peak at earlier ages [38]. Whilst some
increase in incidence may be explained by improvement
in diagnosis and registration [39], the magnitude and con-
sistency of the increase seen in many industrialized coun-
tries suggests other factors, such as socioeconomic status
[40], maternal chemical exposures [41], or pre- and post-
natal exposure to endogenous oestrogens [42] could play
a role.
The marked increases found for female non-gonadal germ
cell tumours in 0–14 year olds and for male non-gonadal
germ cell tumours in 15–24 year olds were based on small
numbers. However, an overall increase (for males and
females combined) in 0–14 year olds has been reported
previously from the Manchester Children's Tumour Regis-
try [14].
The incidence of CNS tumours, especially astrocytomas,
increased amongst both girls and boys aged 0–14 years.
Similar increases in the incidence of childhood CNS
tumours, especially astrocytomas, have been reported
from other studies [14,43,44]. The possible role of artefact
should be acknowledged. The upward trend may be due
to improvements in registration as well as increases in
unknown environmental risk factors [45,46].
The findings of increases for osteosarcoma (females),
gonadal germ cell tumours (females) and non-melanotic
skin cancer (males) were all based on small numbers and
should not be over-interpreted. Indeed, it must be stressed
that there are certain inherent limitations to the present
study. In particular, it should be acknowledged that the
analyses are based on limited numbers of cases from one
geographical area. Differences between male and female
trends were only formally statistically significant for
gonadal tumours in children and melanoma in adoles-
cents/young adults. The interaction for colorectal carci-
noma was based on small numbers of cases. It will be of
great interest to see if similar findings will be reported
from analyses that are conducted in other parts of the UK
and in other countries.
Conclusion
Over the 1968 to 2005 time period there have been signif-
icant temporal changes in the incidence of certain solid
tumours in under-25s in the Northern Region of England.
In some cases marked increases have been found that
merit further attention to identify possible causes and sug-
gest preventative approaches. We have shown there can be
sex-specific changes that may have been obscured or uni-
dentifiable if the sexes were not analysed separately. The
differences shown in melanoma, for instance, point
towards a possible aetiological link with a sex-related
behaviour or exposure.
The causes of different rates may be because of different
exposures, as postulated with melanomas, or due to dif-
ferent susceptibilities, as is possibly the case with thyroid
cancer. Sex-related differences in genetics, exposures,
behaviours and treatment exist even in preadolescentPage 7 of 9
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BMC Cancer 2008, 8:89 http://www.biomedcentral.com/1471-2407/8/89populations and it therefore is necessary to always report
sex-specific data in both childhood and adolescent/young
adult cancers. This will improve our understanding of pat-
terns, trends and aetiology.
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